Stocks and InvestingStocks and Investing
Thu, January 4, 2024
Wed, January 3, 2024
Tue, January 2, 2024
Fri, December 29, 2023

Uy Ear Maintained (ACAD) at Strong Buy with Increased Target to $40 on, Dec 29th, 2023


Published on 2024-10-28 08:08:15 - WOPRAI, Uy Ear
  Print publication without navigation


Uy Ear of Mizuho, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Strong Buy with Increased Target from $35 to $40 on, Dec 29th, 2023.

Uy has made no other calls on ACAD in the last 4 months.



There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 2 agree with Uy's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $27 on, Monday, December 18th, 2023
  • Neena Bitritto-Garg of "Deutsche Bank" Downgraded from Strong Buy to Hold and Held Target at $25 on, Thursday, December 14th, 2023


These are the ratings of the 8 analyists that currently disagree with Uy


  • Jeffrey Hung of "Morgan Stanley" Upgraded from Hold to Buy and Increased Target to $40 on, Tuesday, December 19th, 2023
  • Charles Duncan of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $42 on, Thursday, December 14th, 2023
  • David Hoang of "Citigroup" Initiated at Strong Buy and Held Target at $38 on, Wednesday, December 13th, 2023
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $40 on, Monday, November 6th, 2023
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $33 on, Friday, November 3rd, 2023
  • Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Friday, November 3rd, 2023
  • Ashwani Verma of "UBS" Initiated at Strong Buy and Held Target at $33 on, Tuesday, October 17th, 2023
  • Tessa Romero of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $32 on, Tuesday, October 10th, 2023